276872-82-3 Usage
Uses
Used in Pharmaceutical Research:
(+/-)-N-(t-butoxycarbonyl)-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-piperidine is used as a potential drug candidate for the treatment of various diseases and conditions. Its unique structure and properties make it suitable for further study and development as a potential therapeutic agent.
Used in Medicinal Chemistry:
(+/-)-N-(t-butoxycarbonyl)-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-piperidine is used in medicinal chemistry for the development of new drugs and therapies. Its complex structure and functional groups provide opportunities for modification and optimization to enhance its pharmacological properties and therapeutic potential.
Note: Since the provided materials do not specify the exact applications or industries for (+/-)-N-(t-butoxycarbonyl)-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-piperidine, the uses listed above are general and based on its role in pharmaceutical research and medicinal chemistry. Further information would be needed to provide more specific applications and industries.
Check Digit Verification of cas no
The CAS Registry Mumber 276872-82-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,6,8,7 and 2 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 276872-82:
(8*2)+(7*7)+(6*6)+(5*8)+(4*7)+(3*2)+(2*8)+(1*2)=193
193 % 10 = 3
So 276872-82-3 is a valid CAS Registry Number.
276872-82-3Relevant academic research and scientific papers
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.
Wacker, Dean A,Santella 3rd., Joseph B,Gardner, Daniel S,Varnes, Jeffrey G,Estrella, Melissa,DeLucca, George V,Ko, Soo S,Tanabe, Keiichi,Watson, Paul S,Welch, Patricia K,Covington, Maryanne,Stowell, Nicole C,Wadman, Eric A,Davies, Paul,Solomon, Kimberly A,Newton, Robert C,Trainor, George L,Friedman, Steven M,Decicco, Carl P,Duncia, John V
, p. 1785 - 1789 (2007/10/03)
CCR3 antagonist leads with IC(50) values in the microM range were converted into low nM binding compounds that displayed in vitro inhibition of human eosinophil chemotaxis induced by human eotaxin. In particular, 4-benzylpiperidin-1-yl-n-propylureas and erythro-3-(4-benzyl-2-(alpha-hydroxyalkyl)piperidin-1-yl)-n-propylureas (obtained via Beak reaction of N-BOC-4-benzylpiperidine) exhibited single digit nanomolar IC(50) values for CCR3.
